Pasithea therapeutics announces outcome of pre-ind meeting with fda for pas-004 clinical development

-- company on track to submit pas-004 ind application in current quarter -- -- pasithea plans to begin pas-004 phase 1 dose escalation trial in advanced solid tumor patients harboring ras, raf and nf1 mutations -- south san francisco, calif. and miami, nov. 29, 2023 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, announced receipt of written responses to questions submitted for a type 2 pre-investigational new drug application (ind) meeting with the u.s. food and drug administration (fda) regarding clinical development plan for pas-004.
KTTA Ratings Summary
KTTA Quant Ranking